Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors
US12036203B2 · kind B2 · utility
0Cited by
1References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 10, 2019 |
| Grant date | Jul 16, 2024 |
| Priority date | — |
| Expiry date | Oct 11, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.